🧬 RETATRUTIDE: WHY THREE RECEPTORS?
Retatrutide is being studied as a triple hormone receptor agonist.
One molecule is designed to activate receptors for GIP, GLP-1, and glucagon.
Researchers are studying whether combining those three signaling pathways changes outcomes involving body weight and cardiometabolic biology compared with targeting fewer pathways.
That’s what makes retatrutide scientifically interesting: not simply “another GLP-1,” but a molecule designed around three receptor systems.
As of this post, retatrutide remains investigational and is not FDA-approved.
Research first. Hype second. 🧬